NEW YORK (TheStreet) -- The gluten-free diet movement is all over the news and, more importantly, in more and more restaurants. Reports estimate the size of the gluten-free market to be anywhere from $500 million to $10 billion. That's a rather large expanse, but just view it as growth potential.
A gluten-free diet excludes foods containing a protein composite found in wheat, barley, rye and triticale. It is also the only medically accepted treatment for celiac disease, an illness attacking the small intestine due to the presence of gluten.
There are a few publicly traded companies that sell products aimed largely at consumers honing to a gluten-free diet. They are stocks with small market capitalizations, meaning that share liquidity is low, volatility can be high, factor that can make such stocks difficult or risky to trade.
RiceBran Technologies (RIBT) is a human-food ingredient and animal nutrition based in Scottsdale, Ariz. focused on the procurement, bio-refining and marketing of products derived from rice bran. Rice Bran Technologies has proprietary and patented intellectual property that allows it to convert rice bran, one of the world's most underutilized food sources, into a number of highly nutritious human food ingredient and animal nutrition products.
RiceBran sells products which are used by food manufacturers to create gluten free, hypoallergenic, minimally processed and non-GMO, nutrition-rich products used in pasta, baked goods, pizza dough, cereals, ground meats, healthy beverages and numerous other applications.
RiceBran generated $35 million in revenue in 2013, though it wasn't profitable on the basis of earnings before interest, taxes, depreciation and amortization, or EBITDA, a widely-followed metric. The 2014 forecast is for 69% revenue growth and $2 EBITDA per share. RiceBran has approximately 3 million shares outstanding and a market capitalization of approximately $19 million.